Patients with end-stage type 1 diabetes (T1D) can be effectively managed by allogeneic islet transplantation. However, a severe cadaveric organ shortage greatly limits use of this promising procedure. Stem cells…
Stem cell research offers the promise of replacing missing or damaged tissues in the treatment of disease. Stem-cell-derived transplants still face problems with rejection as in traditional organ transplants. Several…
Diabetes exacts a tremendous toll on patients, their families, and society. Autoimmune Type 1 diabetes, often called juvenile-onset diabetes, is caused by a person’s own immune system mistakenly destroying their…
California's Stem Cell Agency (CIRM) hosted a live Google Hangout about recent progress in stem cell based strategies for diabetes therapies. The speakers included: Francisco Prieto, MD - CIRM's…
CIRM has funded the Diabetes Disease Team led by scientists at ViaCyte, Inc., UCSF, and the La Jolla Institute for Allergy and Immunology. This team aims to bring an embryonic…
Eugene Brandon speaks at the 2011 CIRM Grantee Meeting about Viacyte's efforts to develop a stem cell based treatment for diabetes. CIRM has awarded Viacyte $26 million to support their…
Embryonic stem cells have the potential to help treat 70 or more diseases, but developing those new therapies will take time. Alan Lewis is the former president and CEO of…
Robert Klein, J.D. gave the welcoming remarks for the "Spotlight on Juvenile Diabetes", an educational event presented at the CIRM Governing Board meeting on September 25, 2008. Klein is Chair…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
